Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
High bone tumor burden to identify advanced non-small cell lung cancer patients with survival benefit upon bone targeted agents and immune checkpoint inhibitors.
Manglaviti S, Bini M, Apollonio G, Zecca E, Galli G, Sangaletti S, Labianca A, Sottotetti E, Brambilla M, Occhipinti M, Proto C, Prelaj A, Signorelli D, De Toma A, Viscardi G, Beninato T, Mazzeo L, Bottiglieri A, Leporati R, Fotia G, Ganzinelli M, Portararo P, Garassino MC, de Braud FGM, Lo Russo G, Torri V, Ferrara R. Manglaviti S, et al. Among authors: labianca a. Lung Cancer. 2023 Dec;186:107417. doi: 10.1016/j.lungcan.2023.107417. Epub 2023 Oct 29. Lung Cancer. 2023. PMID: 37918061
Poziotinib for EGFR and HER2 exon 20 insertion mutation in advanced NSCLC: Results from the expanded access program.
Prelaj A, Bottiglieri A, Proto C, Lo Russo G, Signorelli D, Ferrara R, Galli G, De Toma A, Viscardi G, Brambilla M, Lobefaro R, Nichetti F, Manglaviti S, Occhipinti M, Labianca A, Ganzinelli M, Gallucci R, Zilembo N, Greco GF, Torri V, de Braud F, Garassino MC. Prelaj A, et al. Among authors: labianca a. Eur J Cancer. 2021 May;149:235-248. doi: 10.1016/j.ejca.2021.02.038. Epub 2021 Apr 2. Eur J Cancer. 2021. PMID: 33820681
Body mass index (BMI) and outcome of metastatic melanoma patients receiving targeted therapy and immunotherapy: a multicenter international retrospective study.
Rutkowski P, Indini A, De Luca M, Merelli B, Mariuk-Jarema A, Teterycz P, Rogala P, Lugowska I, Cybulska-Stopa B, Labianca A, Di Guardo L, Del Vecchio M, Pigozzo J, Randon G, Corti F, Tondini CA, Rulli E, Mandala M. Rutkowski P, et al. Among authors: labianca a. J Immunother Cancer. 2020 Nov;8(2):e001117. doi: 10.1136/jitc-2020-001117. J Immunother Cancer. 2020. PMID: 33203662 Free PMC article.
Timing of sentinel node biopsy independently predicts disease-free and overall survival in clinical stage I-II melanoma patients: A multicentre study of the Italian Melanoma Intergroup (IMI).
Mandalà M, Galli F, Patuzzo R, Maurichi A, Mocellin S, Rossi CR, Rulli E, Montesco M, Quaglino P, Caliendo V, De Giorgi V, Merelli B, Caracò C, Piazzalunga D, Labianca A, Ribero S, Senetta R, Gianatti A, Valeri B, Massi D, Ascierto PA, Santinami M; Italian Melanoma Intergroup (IMI). Mandalà M, et al. Among authors: labianca a. Eur J Cancer. 2020 Sep;137:30-39. doi: 10.1016/j.ejca.2020.07.001. Epub 2020 Jul 30. Eur J Cancer. 2020. PMID: 32739767 Free PMC article.
The prognostic impact of the extent of ulceration in patients with clinical stage I-II melanoma: a multicentre study of the Italian Melanoma Intergroup (IMI).
Portelli F, Galli F, Cattaneo L, Cossa M, De Giorgi V, Forte G, Fraternali Orcioni G, Gianatti A, Indini A, Labianca A, Maurichi A, Merelli B, Montesco MC, Occelli M, Patuzzo R, Piazzalunga D, Pigozzo J, Quaglino P, Ribero S, Salvatori R, Saraggi D, Sena P, Senetta R, Valeri B, Tanaka M, Fukayama M, Palmieri G, Mandalà M, Massi D; Italian Melanoma Intergroup (IMI). Portelli F, et al. Among authors: labianca a. Br J Dermatol. 2021 Feb;184(2):281-288. doi: 10.1111/bjd.19120. Epub 2020 Jun 15. Br J Dermatol. 2021. PMID: 32282932
Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanoma.
Owen CN, Bai X, Quah T, Lo SN, Allayous C, Callaghan S, Martínez-Vila C, Wallace R, Bhave P, Reijers ILM, Thompson N, Vanella V, Gerard CL, Aspeslagh S, Labianca A, Khattak A, Mandala M, Xu W, Neyns B, Michielin O, Blank CU, Welsh SJ, Haydon A, Sandhu S, Mangana J, McQuade JL, Ascierto PA, Zimmer L, Johnson DB, Arance A, Lorigan P, Lebbé C, Carlino MS, Sullivan RJ, Long GV, Menzies AM. Owen CN, et al. Among authors: labianca a. Ann Oncol. 2021 Jul;32(7):917-925. doi: 10.1016/j.annonc.2021.03.204. Epub 2021 Mar 30. Ann Oncol. 2021. PMID: 33798657 Free article.
Corrigendum to "Timing of sentinel node biopsy independently predicts disease-free and overall survival in clinical stage I-II melanoma patients: A multicenter study of the Italian Melanoma Intergroup (IMI)" [Eur J Canc 137 (2020). Pages 30-39].
Mandalà M, Galli F, Patuzzo R, Maurichi A, Mocellin S, Rossi CR, Rulli E, Montesco M, Quaglino P, Caliendo V, De Giorgi V, Merelli B, Caracò C, Piazzalunga D, Labianca A, Ribero S, Senetta R, Gianatti A, Valeri B, Massi D, Ascierto PA, Santinami M; Italian Melanoma Intergroup (IMI). Mandalà M, et al. Among authors: labianca a. Eur J Cancer. 2020 Nov;139:204-205. doi: 10.1016/j.ejca.2020.09.002. Epub 2020 Sep 23. Eur J Cancer. 2020. PMID: 32980191 Free PMC article. No abstract available.
Multimodal Treatment of Advanced Mucosal Melanoma in the Era of Modern Immunotherapy.
Teterycz P, Czarnecka AM, Indini A, Spałek MJ, Labianca A, Rogala P, Cybulska-Stopa B, Quaglino P, Ricardi U, Badellino S, Szumera-Ciećkiewicz A, Falkowski S, Mandala M, Rutkowski P. Teterycz P, et al. Among authors: labianca a. Cancers (Basel). 2020 Oct 26;12(11):3131. doi: 10.3390/cancers12113131. Cancers (Basel). 2020. PMID: 33114734 Free PMC article.
16 results